Phase INeuropeptide
Compound 61428
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061428
Risk Class
MODERATE
Last Audit
Feb 4, 2108
Research Abstract
Neuropeptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61428 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061428 with updates logged 2108-02-04.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61428Neuropeptide Program 61428
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061428
- [2] Operations Pulse • Neuropeptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61428